Clinical trials: Retinal Vascular
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2
Diabetes Visual Function Supplement Study
This study will evaluate the effects of a novel multi-component dietary supplement on the visual function and retinal structure of patients with diabetes with both no diabetic retinopathy and mild to moderate diabetic…
- Conditions
- Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
- Trial name
- DiVFuSS (NCT01646047)
- Testing
- multi-component nutritional supplement capsules, multi-component dietary supplement
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- ZeaVision, LLC
Diabetic Retinopathy, Macular Edema
A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
Researchers are looking for new ways to treat diabetic macular edema (DME). In this trial, researchers want to learn if a trial medicine called MK-8748 can treat DME.
- Trial name
- NCT07705555
- Testing
- MK-8748, Aflibercept
- Where
- 33 sites in United States, Argentina and 2 more
- Volunteers
- 960 people
- Sponsor
- Merck Sharp & Dohme LLC
Retina Vascular Pathology
Evaluation of RTVue XR With SSADA
Optovue has implemented a motion contrast imaging software in RTVue XR, a split spectrum amplitude decorrelation algorithm (SSADA), for non-invasive imaging of ocular vasculature.
- Trial name
- NCT02535520
- Volunteers
- 155 people
- Sponsor
- Optovue
Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME).
- Trial name
- ALTITUDE® (NCT04567550)
- Testing
- ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2, ABBV-RGX-314 Dose 3
- Where
- 25 sites in United States
- Volunteers
- 139 people
- Sponsor
- AbbVie
Diabetic Retinopathy
Trial to Assess the Efficacy of Neuroprotective Drugs Administered Topically to Prevent or Arrest Diabetic Retinopathy
To assess whether neuroprotective drugs administered topically (somatostatin and brimonidine) are able to prevent or arrest the development and progression of neurodegenerative changes
- Trial name
- EUROCONDOR (NCT01726075)
- Testing
- COLIRIOBCN070660, Brimonidine
- Where
- 11 sites in Denmark, France and 5 more
- Volunteers
- 450 people
- Sponsor
- BCN Peptides
Diabetic Retinopathy
Protein Kinase C (PKC) Inhibitor-Diabetic Retinopathy Phase 3 Study
This study is to test whether or not 32 milligrams (mg) of ruboxistaurin a day over three years will reduce vision loss associated with diabetic retinopathy.
- Trial name
- NCT00604383
- Testing
- ruboxistaurin
- Where
- United States
- Volunteers
- 685 people
- Sponsor
- Chromaderm, Inc.
Age-Related Macular Degeneration (AMD), Macular Degeneration
X-82 to Treat Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of X-82 in the treatment of vision loss due to wet AMD.
- Conditions
- Age-Related Macular Degeneration (AMD), Macular Degeneration, Exudative Age-related Macular Degeneration, AMD
- Trial name
- NCT02348359
- Testing
- X-82, Anti-VEGF
- Where
- 35 sites in United States
- Volunteers
- 157 people
- Sponsor
- Tyrogenex
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Telangiectasis, Idiopathic Juxtafoveal Retinal Telangiectasia
A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)
This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in reducing central subfield thickness (CST) and improving best-corrected visual acuity (BCVA) in…
- Trial name
- NCT03669393
- Testing
- THR-317 8mg
- Where
- 3 sites in France, Switzerland
- Volunteers
- 8 people
- Sponsor
- ThromboGenics
Branch Retinal Vein Occlusion
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
The purpose of this study was to evaluate the efficacy and safety of brolucizumab in treatment of patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO).
- Trial name
- RAPTOR (NCT03802630)
- Testing
- Brolucizumab 6 mg, Aflibercept 2 mg
- Where
- 102 sites in United States, Austria and 17 more
- Volunteers
- 450 people
- Sponsor
- Novartis Pharmaceuticals
Retinal Vein Occlusion
Efficacy and Safety of Conbercept in Macular Edema Secondary to Retinal Vein Occlusion
This is a Phase II, single arm, open label clinical trial. 60 RVO patients (including 30 BRVO and 30 CRVO, respectively) are enrolled in the study.
- Trial name
- FALCON (NCT01809236)
- Testing
- Conbercept
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Chengdu Kanghong Biotech Co., Ltd.
Macular Edema, Retinal Vein Occlusion
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Patients With Macular Edema Due to Retinal Vein Occlusion (RVO)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept, in participants with macular edema due to treatment-naïve branch (BRVO) or central retinal vein occlusion (CRVO).
- Trial name
- BEACON (NCT04592419)
- Testing
- KSI-301, Aflibercept
- Where
- 141 sites in United States, Czechia and 10 more
- Volunteers
- 568 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema, Diabetic Retinopathy
ADVM-022 Intravitreal Gene Therapy for DME
A Phase 2, Multi-Center, Randomized, Double-Masked*, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects with Diabetic Macular Edema [INFINITY]
- Trial name
- INFINITY (NCT04418427)
- Testing
- 6E11 vg/eye of ADVM-022, 2E11 vg/eye of ADVM-022, Aflibercept
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 36 people
- Sponsor
- Adverum Biotechnologies, Inc.
Diabetes Mellitus, Diabetic Retinopathy
A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.
This study is conducted to select the THR-687 dose level (Part A of the study) and to assess the efficacy and safety of the selected dose level compared to aflibercept (Part B of the study).
- Conditions
- Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- INTEGRAL (NCT05063734)
- Testing
- THR-687 dose level 1, THR-687 dose level 2, THR-687 selected dose level
- Where
- 25 sites in United States, Estonia and 3 more
- Volunteers
- 16 people
- Sponsor
- Oxurion
Central Retinal Vein Occlusion
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
Provide efficacy and safety data on intravitreal injections of ranibizumab 0.5 mg in patients with visual impairment due to macular edema secondary to CRVO
- Trial name
- Camellia (NCT01976312)
- Testing
- Ranibizumab 0.5 mg
- Where
- 34 sites in China, Hong Kong and 5 more
- Volunteers
- 252 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Retinopathy
Extension Study of the Long-term Safety and Tolerability of Octreotide Acetate in Patients With Moderately Severe or Severe Non-proliferative Diabetic Retinopathy or Low Risk Proliferative Diabetic Retinopathy
This multicenter, open-label extension study will evaluate the long-term tolerability and safety for patients completing study CSMS995 0802.
- Trial name
- NCT00248157
- Testing
- Octreotide acetate in microspheres
- Volunteers
- 105 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Neuropathies, Diabetic Foot
Thermal Screening for Early Diabetic Peripheral Neuropathy (DPN)
The goal of this research is to develop better tools for diagnosing illness of the feet and legs of people who have diabetes. Investigators will use thermal videos of the foot to aid in the refinement of a system designed to…
- Conditions
- Diabetic Neuropathies, Diabetic Foot, Diabetic Retinopathy
- Trial name
- NCT03069729
- Testing
- no intervention
- Where
- United States
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- VisionQuest Biomedical LLC
Diabetic Retinopathy
A Safety and Efficacy Study of Vitreosolve® for Non-Proliferative Diabetic Retinopathy Subjects
The purpose of this study is to determine the safety and efficacy of Vitreosolve in diabetic retinopathy patients.
- Trial name
- NCT00664183
- Testing
- Vitreosolve
- Where
- 17 sites in United States, India
- Volunteers
- 400 people
- Sponsor
- Vitreoretinal Technologies, Inc.
Macular Edema, Cystoid, Retinal Vein Occlusion
The Standard Care vs. COrticosteroid for REtinal Vein Occlusion (SCORE) Study
The SCORE Study will compare the effectiveness and safety of standard care to intravitreal injection(s) of triamcinolone for treating macular edema (swelling of the central part of the retina) associated with central retinal vein…
- Trial name
- SCORE (NCT00105027)
- Testing
- Standard Care, intravitreal triamcinolone injection
- Where
- United States
- Volunteers
- 682 people
- Sponsor
- The Emmes Company, LLC
Diabetic Retinopathy (DR), Diabete Mellitus
Clinical Efficacy of Implementing an AI-SaMD for Funduscopy Analysis in Patients With Diabetes Mellitus
The objective of this study is to investigate the efficacy of implementing the AI-SaMD(VUNO Med®-Fundus AI™) alongside routine clinical practice for the detection of diabetic retinopathy.
- Conditions
- Diabetic Retinopathy (DR), Diabete Mellitus, Fundus Photography
- Trial name
- SAFE-DM (NCT07378956)
- Testing
- VUNO Med®-Fundus AI™
- Where
- South Korea
- Volunteers
- 340 people
- Sponsor
- VUNO Inc.